OCCPR: A Leader in Cancer Proteomics and Proteogenomics

The mission of the NCI’s Office of Cancer Clinical Proteomics Research (OCCPR) is to improve prevention, early detection, diagnosis, and treatment of cancer by enhancing the understanding of the molecular mechanisms of cancer, advance proteome and proteogenome science and technology development through community resources (data and reagent), and accelerate the translation of molecular findings into the clinic. This is achieved through OCCPR-supported programs such as the Clinical Proteomic Tumor Analysis Consortium (CPTAC), partnerships with Federal agencies, and collaborations with international organizations/institutions.

Proteogenomics Research

Preoteogenomics Research – On the Frontier of Precision Medicine

Learn about cancer genomics, how it is being integrated with proteomics (termed proteogenomics), and how proteogenomics is anticipated to improve precision medicine.

VIDEO: Dr. Henry Rodriguez - Proteogenomics in Cancer Medicine

Dr. Henry Rodriguez, director of the Office of Cancer Clinical Proteomics Research (OCCPR) at NCI, speaks with ecancer television at WIN 2017 about the translation of the proteins expressed in a patient's...


CPTAC Announces New PTRCs, PCCs, and PGDACs

This week, the Office of Cancer Clinical Proteomics Research (OCCPR) at the National Cancer Institute (NCI), part of the National Institutes of Health, announced its aim to further the convergence of proteomics with genomics – “proteogenomics,” to better understand the molecular basis of cancer...


NCI-CPTAC DREAM Proteogenomics Challenge (Registration Now Open)

Proteogenomics, integration of proteomics, genomics, and transcriptomics, is an emerging approach that promises to advance basic, translational and clinical research.  By combining genomic and proteomic information, leading scientists are gaining new insights due to a more complete and unified...


CPTAC Investigators Identify Rogue Breast Tumor Proteins That Point To Potential Drug Therapies

For patients with difficult-to-treat cancers, doctors increasingly rely on genomic testing of tumors to identify errors in the DNA that indicate a tumor can be targeted by existing therapies. But this approach overlooks another potential marker — rogue proteins — that may be driving cancer cells...


Fred Hutch's Paulovich Laboratory to Lead Protein Assay Work for National Beau Biden Cancer Moonshot

The Applied Proteogenomics OrganizationaL Learning and Outcomes (APOLLO) network, which is a partnership among the National Cancer Institute, Department of Defense, and Department of Veterans Affairs, has tapped the Paulovich Laboratory at Fred Hutchinson Cancer Research Center to create a panel...


PODCAST: Dr. Warren Kibbe & Dr. Henry Rodriguez: Working toward a cure for cancer

The Obama administration's cancer moonshot has brought three Federal agencies together. Specifically, the National Cancer Institute (NCI), the Department of Defense (DoD), and the Department of Veterans Affairs (VA) have formed a new collaboration using state-of-the-art research methods in...


At the United Nation Foundation's Social Good Summit, Vice President Biden Announces New Cancer Moonshot International Cooperation and Investments

This week, Vice President Joe Biden announced progress on his global vision for the Cancer Moonshot.  Announced were 10 new Memoranda of Understanding or Memoranda of Cooperation for international cancer research and care, as well as new efforts in the emerging scientific areas of precision...


University of Victoria Genome British Columbia Proteomics Centre Partners with CPTAC

University of Victoria Genome British Columbia Proteomics Centre, a leader in proteomic technology development, has partnered with the U.S. National Cancer Institute (NCI) to make targeted proteomic assays accessible to the community through NCI’s CPTAC Assay Portal (...


Pages